New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 1, 2014
08:32 EDTBAYRY, MRKBayer plans to keep Coppertone, Dr. Scholl's from Merck, Reuters says
Bayer (BAYRY) plans to hold on to non-drug consumer brands in its $14.2B buyout of Merk's (MRK) consumer care division, reports Reuters. According to several people with knowledge of the approaches, Bayer is being courted by rivals keen to acquire Coppertone and Dr. Scholl's although it is not planning to untie the Merck bundle. Reference Link
News For BAYRY;MRK From The Last 14 Days
Check below for free stories on BAYRY;MRK the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
July 30, 2014
05:55 EDTBAYRYBayer says Stivargahas approved in Europe for GIST
Subscribe for More Information
July 29, 2014
12:13 EDTMRKOn The Fly: Midday Wrap
Subscribe for More Information
09:44 EDTMRKMerck CEO says has not been urged for big consolidation deal, CNBC says
Subscribe for More Information
08:32 EDTMRKMerck says not interested in deal solely, primarily for inversion
Subscribe for More Information
07:19 EDTMRKCBI to hold a conference
Subscribe for More Information
06:59 EDTMRKMerck sees FY14 revenue $42.4B-$43.2B, consensus $42.56B
Subscribe for More Information
06:58 EDTMRKMerck reports Q2 Januvia sales $1.58B, Q2 Zetia sales $1.13B
Reports Q2 Remicade sales $607M; Q2 Isentress sales $453M; Q2 Gardasili sales $409M; Q2 Proquad sales $326M; Q2 Singulair sales $284M; Q2 Nanosex sales $258M.
06:57 EDTMRKMerck sees FY14 non-GAAP EPS $3.43-$3.53, consensus $3.48
Subscribe for More Information
06:57 EDTMRKMerck reports Q2 non-GAAP EPS 85c, consensus 81c
Subscribe for More Information
July 28, 2014
15:47 EDTMRKNotable companies reporting before tomorrow's open
Subscribe for More Information
14:03 EDTMRKEarnings Preview: Merck's pharmaceutical sales dependent on newer drugs
Subscribe for More Information
10:36 EDTMRKMerck August weekly volatility elevated into Q2 and outlook
Merck August weekly call option implied volatility is at 26, August is at 16, September is at 15, January is at 16; compared to its 26-week average of 18 according to Track Data, suggesting large near term price movement into the expected release of Q2 result on July 29.
July 25, 2014
07:32 EDTBAYRYAmerican Veterinary Medical Association to hold a conference
Subscribe for More Information
05:35 EDTBAYRYBayer, Onyx reports NEXAVAR Phase 3 trial did not meet primary endpoint
Subscribe for More Information
July 24, 2014
13:06 EDTBAYRYBayer treatment for systemic sclerosis receives FDA orphan designation
Subscribe for More Information
08:32 EDTMRKMerck initiates Phase 3 study of Letermovir
Subscribe for More Information
07:12 EDTBAYRYEvogene announces amendment to Bayer wheat agreement
Subscribe for More Information
July 21, 2014
07:21 EDTMRKGilead could be hurt by new HCV drugs, says Wells Fargo
Noting that data on a new Merck (MRK) HCV treatment is expected in November, Wells Fargo thinks Merck's HCV drug could be combined with Gilead's (GILD) Sovaldi to shorten the duration of treatment to four weeks. Other companies could take similar actions, and Gilead's per patient revenues would be significantly reduced if this occurs, the firm warned. However, it continues to have an upbeat outlook on Gilead heading into what it sees as a strong quarter and is still upbeat on the company's long-term HCV opportunity. It keeps an Outperform rating on Gilead.
07:14 EDTBAYRYAmerican Association of Physicists in Medicine to hold annual meeting
56th Annual Meeting of AAPM to be held in Austin, Texas on July 20-25.
06:43 EDTMRKGrowing market for hepatitis-C treatment prompts legal scramble, WSJ says
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use